指南与共识免疫规划慢病防控与筛查

指南推荐哮喘儿童常规使用减毒活流感疫苗的安全性评估

Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma.
指南 / 共识 · Vaccine · 2019-06-10

该研究评估了推荐2岁及以上哮喘儿童使用减毒活流感疫苗(LAIV)的指南是否增加接种后21或42天内下呼吸道事件(LRE)风险。采用前后对照回顾性队列设计,纳入2007至2016年两个大型医疗集团中2-17岁哮喘儿童。结果显示,实施LAIV指南未增加LRE风险,调整后率比(aROR)在21天为0.74(95%CI 0.43-1.29),42天为0.77(95%CI 0.53-1.14)。

要点

  • 推荐哮喘儿童使用LAIV的指南未增加接种后21或42天内下呼吸道事件风险。
  • 2-4岁和5-18岁年龄亚组中,LAIV指南与下呼吸道事件风险增加无关。
  • 研究期间LAIV指南组接种LAIV比例从23%升至68%,对照组从7%升至11%。

核心结论

  • 在大型哮喘儿童队列中,推荐LAIV而非灭活流感疫苗(IIV)的指南未增加接种后下呼吸道事件。

研究设计与样本

  • 前后对照回顾性队列研究,纳入2007至2016年两个大型医疗集团中2-17岁哮喘儿童,共4771名儿童接受7851剂次流感疫苗接种。

主要发现

  • LAIV指南组接种LAIV比例从23%升至68%,对照组从7%升至11%。
  • 调整年龄和基线哮喘严重程度后,接种后21天内LRE的aROR为0.74(95%CI 0.43-1.29),42天内为0.77(95%CI 0.53-1.14)。
  • 2-4岁儿童21天内LRE的aROR为0.92(95%CI 0.34-2.53),42天内为0.94(95%CI 0.49-1.82)。
  • 5-18岁儿童21天内LRE的aROR为0.58(95%CI 0.26-1.30),42天内为0.67(95%CI 0.37-1.23)。

关键数值与推荐

  • 指南推荐2岁及以上哮喘儿童使用LAIV,主要结局为接种后21天和42天内就医的下呼吸道事件(主要为哮喘急性发作)。

临床怎么用

  • 可为2岁及以上哮喘儿童常规接种LAIV提供安全性证据,支持指南推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate whether a guideline recommending Live Attenuated Influenza Vaccine (LAIV) for children 2 years and older with asthma increased risks for lower respiratory events (LREs), within 21 or 42 days of vaccination, as compared to standard guidelines to administer Inactivated Influenza Vaccine (IIV) in children with asthma. METHODS: This was a pre/post guideline retrospective cohort study of children ages 2-17 years with asthma and receiving one or more influenza vaccines in two large medical groups from 2007 to 2016. Both groups recommended IIV in the pre-period; in 2010, one group implemented a guideline recommending LAIV for all children, including those with asthma. Main outcomes were medically attended LREs within 21 and 42 days after influenza immunization. Analysis used a generalized estimating equation regression to estimate the ratio of rate ratios (RORs) comparing pre/post events between LAIV guideline and control group. RESULTS: The cohort included 7851 influenza vaccinations in 4771 children with asthma. Among patients in the LAIV guideline group, the proportion receiving LAIV increased from 23% to 68% post-guideline implementation, versus an increase from 7 to 11% in the control group. Age and baseline asthma severity adjusted ROR showed no increase in LREs, primarily asthma exacerbations, following implementation of the LAIV guideline: overall aROR (95% Confidence Interval): 0.74 (0.43-1.29) for LRE within 21 days of vaccination, 0.77 (0.53-1.14) for LRE within 42 days of vaccination. For the subset of children ages 2-4 years aROR: 0.92 (0.34-2.53) for LRE within 21 days of vaccination and 0.94 (0.49-1.82) for LRE within 42 days of vaccination; for children 5-18 years aROR (95% CI): 0.58 (0.26-1.30) for LRE within 21 days of vaccination and 0.67 (0.37-1.23) for LRE within 42 days. CONCLUSION: In a large cohort of children with asthma, a guideline recommending LAIV rather than IIV did not increase LREs following vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nordin JD, Vazquez-Benitez G, Olsen A, et al. Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma. Vaccine. 2019. PMID: 31196683. doi:10.1016/j.vaccine.2019.05.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。